Keller, Kaylee M.
Koetsier, Joost
Schild, Linda
Amo-Addae, Vicky
Eising, Selma
van den Handel, Kim
Ober, Kimberley
Koopmans, Bianca
Essing, Anke
van den Boogaard, Marlinde L.
Langenberg, Karin P. S.
Jäger, Natalie
Kool, Marcel
Pfister, Stefan
Dolman, M. Emmy M.
Molenaar, Jan J.
van Hooff, Sander R.
Funding for this research was provided by:
Innovative Medicines Initiative (116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064, 116064)
HORIZON EUROPE European Research Council (716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079, 716079)
KWF Kankerbestrijding (8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351, 8351)
Article History
Received: 27 September 2022
Accepted: 15 November 2022
First Online: 5 April 2023
Declarations
:
: Not applicable.
: All authors have approved the manuscript for submission.
: The authors declare that they have no competing interests.